Abstract
The frequency of ADHF is increasing and its mortality and early readmission rates are high. It is usually superimposed on chronic HF, but it can be the initial manifestation of this disease. There is a wide variety of inciting factors as well as significant comorbidities in most patients with ADHF. The maladaptive compensatory NH mechanisms that contribute to chronic HF are also operative in ADHF. Conventional therapy with diuretics and positive inotropic agents has early beneficial effects, but these methods can further augment adverse NH activation. The cardiorenal syndrome is a particularly challenging complication whose mechanisms have not been clarified. It is anticipated that current studies on mechanisms of this syndrome and its therapy will result in enhanced management.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102:14–23.
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. Circulation. 2005;112:3958–68.
Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–68.
Staub NC, Nagano H, Pearce ML. Pulmonary edema in dogs, especially the sequence of fluid accumulation in lungs. J Appl Physiol. 1967;22:227–40.
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction SOLVD. Circulation. 1990;82:1724–9.
Summers R, Amsterdam E. Pathophysiology of acute decompensated heart failure. J Am Coll Cardiol. 2005;46:65–7.
Sampson JJ, Leeds SE, Uhley HN, Friedman M. The lymphatic system in pulmonary disease. In: Mayerson HS, editor. Lymph and the lymphatic system. Springfield, IL: Charles C. Thomas; 1968. p. 200.
Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376–82.
Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for Âdecompensated heart failure. Am J Cardiol. 2003;91:245–8.
Aronson D, Burger AJ. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol. 2003;26:703–10.
Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92:222–6.
Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14:515–21.
Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J. 2006;151:845–50.
Peschel T, Schonauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609–14.
Peacock WF, Allegra J, Ander D, et al. Management of acute decompensated heart failure in the emergency department. Congest Heart Fail. 2003;9 Suppl 1:S3–18.
Rame JE, Sheffield MA, Dries DL, et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. Am Heart J. 2001;142:714–9.
Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;15(6): 257–60.
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–53.
Maisel AS, McCord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010–7.
Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute decompensated heart failure national registry analysis). J Am Coll Cardiol. 2008;52:534–40.
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55:53–60.
Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: Guyton revisited. Eur Heart J. 2005;26:11–7.
Liang K, Williams A, Greene E. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36 Suppl 1:S75–88.
Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy CW, Young JB. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168:847–54.
Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, Liu PP, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghiade M. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol. 2009;53:254–63.
Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Amsterdam, E.A., Tong, K.L., Summers, R. (2012). Pathophysiology of Acute Decompensated Heart Failure. In: Peacock, W. (eds) Short Stay Management of Acute Heart Failure. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-627-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-61779-627-2_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-626-5
Online ISBN: 978-1-61779-627-2
eBook Packages: MedicineMedicine (R0)